ERNA - Company ID 0000748592
The table below shows Eterna Therapeutics Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$7.02M | -$15.84M | -$20.41M | -$20.98M | -$23.49M | -$8.10M |
| Capital expenditure | $37.00K | $369.00K | $19.00K | $297.00K | $154.00K | $39.00K |
| Investing cash flow | -$37.00K | -$365.00K | -$19.00K | -$47.00K | -$22.74M | -$39.00K |
| Dividends paid | - | - | - |
Eterna Therapeutics Inc. reported operating cash flow of -$7.02M for fiscal year 2025. That is up 55.7% from -$15.84M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from $23.00K (FY 2016) to -$7.02M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $7.21M | $6.26M | $16.56M | $19.58M | $61.59M | $4.67M |